No black box warning on record for Sohonos

As of the latest FDA labeling reviewed, Sohonos (PALOVAROTENE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Sohonos medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Premature Epiphyseal Closure: Premature epiphyseal closure occurred with SOHONOS. Assess baseline skeletal maturity before SOHONOS therapy and monitor linear growth in growing pediatric patients ( 5.2 ) Mucocutaneous Adverse Reactions: Dry skin, lip dry, pruritus, rash, alopecia, erythema, skin exfoliation, and dry eye occurred with SOHONOS. Prevent or treat with skin em

No black box warning on record for Sohonos

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Premature Epiphyseal Closure: Premature epiphyseal closure occurred with SOHONOS. Assess baseline skeletal maturity before SOHONOS therapy and monitor linear growth in growing pediatric patients ( 5.2 ) Mucocutaneous Adverse Reactions: Dry skin, lip dry, pruritus, rash, alopecia, erythema, skin exfoliation, and dry eye occurred with SOHONOS. Prevent or treat with skin em

Sohonos Black Box Warning

No black box warning on record for Sohonos

Other warnings & precautions

Sohonos Black Box Warning

No black box warning on record for Sohonos

Other warnings & precautions